Multiple Myeloma News
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics
Cytovia Therapeutics has entered a research and licensing agreement with Inserm, the French National Institute of Health and Medical Research, to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of multiple myeloma....
Scientists Develop a ‘Dual-CAR’ Targeting Two Multiple Myeloma-associated Antigens
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable successes in fighting B cell leukemias/lymphomas and numerous CAR-T's are being developed for use in multiple myeloma. While primising results have been reported with BCMA CAR T cells, responses do...
Teclistamab is an Active T Cell–Redirecting Bispecific Antibody Against BCMA for Multiple Myeloma
The success of T cell–mediated therapeutics depends, in part, on the selective expression of cell surface target epitopes to minimize the off-tissue toxicity. B-Cell Maturation Antigen (BCMA) is a protein that is selectively expressed on late-stage B cells and plasma...
BMS/Celgene Called Out by House Oversight Committee on Drug Pricing of Revlemid
House Oversight Committee hold hearings on drug Pricing. The Committee is holding two days of hearings with top executives of major drug companies to examine their pricing practices for some of the costliest drugs in the United States. The hearings, titled...
Oncopeptides Launches Melflufen Expanded Access Program in US
Oncopeptides announced today that the Melflufen open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. EAPs are designed to provide patients living with serious or life-threatening conditions access to investigational medicines when...
ONCOTracker and the Binding Site Collaborate to Develop sBCMA Monitoring Test
ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the B-cell maturation antigen (sBCMA) protein to monitor people with blood cancers, including multiple myeloma. Serum B-cell maturation...
Tandem Auto-ASCT Has Better Overall Survival Compared to Auto-ASCT Only
Updated results from a previously published cohort was published in Clinical Transplant. 92 newly diagnosed myeloma patients who received tandem transplant were compared them with 81 contemporary patients who received autologous transplant only. With a median...
FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...
Ide-cel (Anti-BCMA CAR T Cell Therapy) Granted FDA Priority Review for Heavily-treated Multiple Myeloma
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...
FDA Approves Selinexor for Heavily Treated RRMM Patients
The U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four...
Other Oncology News
- U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma(BMS) Oct 19, 2020 - Bristol Myers Squibb and Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and supplemental New Drug Application (sNDA), respectively, for OPDIVO® (nivolumab) in combination with CABOMETYX® (cabozantinib) for patients with advanced renal cell… Read more »
- Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer(Merck) Oct 16, 2020 - Merck, known as MSD outside the United States and Canada, today announced positive results from two studies from the company’s leading lung cancer clinical development program evaluating KEYTRUDA, Merck’s anti-PD-1 therapy: KEYTRUDA in combination with chemotherapy (KEYNOTE-021 [Cohort G]) and KEYTRUDA in combination with quavonlimab… Read more »
- OneOncology Launches OneR, a Community Oncology Research Network(OneOncology) Oct 18, 2020 - OneOncology, the partnership of independent oncology practices, today announced the formation of a separate subsidiary, the OneOncology Research Network (OneR). OneR is a national non-exclusive clinical trial site management organization (SMO) that will enhance the current high-performing research programs underway at participating community oncology practices… Read more »
- Roche Announces Full FDA Approval For Venclexta Combinations For Acute Myeloid Leukaemia(Roche) Oct 19, 2020 - Roche today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or… Read more »
Additional Myeloma News
Powered by:
- Sanofi’s Sarclisa Bags NICE Recommendation
- Daratumumab-Based Regimen May Be Superior for First-Line Multiple Myeloma Treatment
- Penn Researchers Discover Potential Cause of Immunotherapy-Related Neurotoxicity, Chart Path Forward
- Genmab Shares Drop On Legal Battle With J&J Over Cancer Drug
- U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
- As Myeloma Options Increase, So Do Challenges
- GSK Highlights Scientific Advances Across Its Growing Oncology Portfolio At ESMO Virtual Congress 2020
- SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
- Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma
- Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.